A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with 5-Azacytidine in Patients with Recurrent, Resectable Osteosarcoma
Administered By
Awarded By
Contributors
- Wagner, Lars Martin Principal Investigator
Start/End
- February 26, 2021 - June 30, 2023